Endeavor

Life Science Innovation in Biotechnology, AI, Drug Discovery, Medical Devices, Medical Technology, Health and Wellness, Bio-agriculture,

Dr. Martin Alexander Gershon, MD, JD, MPH is the Managing Partner and CIO of Endeavor Life Sciences Venture Funds and Venture Studio, Host of BetterHealth Iconic Webinar Series, and Senior Executive Investor-in-Residence for Healthcare at Techstars and a member of the Techstars NY Powered by J.P. Morgan Selection Committee.

Endeavor Life Science Venture Funds is a Series B evergreen fund and Venture Studio for Seed and Series A. The fund has invested in 141 investments in groundbreaking biotech and healthcare companies including Moderna and AI and digital healthcare companies like Grail. Endeavor opportunistically invests in drug discovery and development, rare diseases, AI driven diagnostics / biomarkers and medical devices, mental health, women’s health, is a strong supporter of women CEOs and CEOs from diverse communities.

We believe passionately that technology and outstanding entrepreneurs with great scientific innovations can play a role in improving health outcomes and providing a real long term pathway for all people to live a healthier life, every day.

Endeavor’s portfolio companies possess disruptive technologies, with strong scalable commercial potential, driven by great CEO entrepreneurs who look to develop partnerships within the Endeavor ecosystem to help them build their companies into the next great unicorns. We are driven by our core principles to bring together exceptionally talented entrepreneurs, financial, strategic and operational resources, and real-life proven expertise in an ecosystem where we can do the greatest good to improve access and delivery of healthcare.

Endeavor has created an ecosystem that creates resilient CEO/Entrepreneurs and sustainable funding for development, growth, commercialization and scalability from Seed Stage to Series B. Endeavor has designed a funnel within our ecosystem that moves our companies from the Venture Studio, to Venture Fund, and ultimately moves our companies into Corporate Accelerators and Corporate Venture who collectively have designed a clear entry and exit path of increasing investment and integration into their corporate ecosystem leading to eventual acquisition. We believe this Future Proofs our portfolio companies, building great leaders, strong teams, and companies that can withstand any crisis.

Dr. Gershon is the former Chief Innovation and Investment Officer of Life Sciences at McGill University Medical Center, Aspen Institute Business of Health Chair and Senior Fellow, Memorial Sloan-Kettering Cancer Center Mayday Fellow, Harvard, McGill and Columbia trained neuroscientist, oncologist and immunologist, FDA attorney, Lecturer of Drug Development and Drug Discovery Harvard and MIT Health Science and Technology Program, Professor and Senior Lecturer of Healthcare Innovation and Entrepreneurship Johns Hopkins, Columbia, McGill Universities, Guest Lecturer of Healthcare AI and Digital Innovation and Commercialization NYU and Johns Hopkins Carey School of Business, Lecturer of Social Entrepreneurship Oxford and Professor University of Geneve Business School, Executive-in-Residence Matter Health, and Special Advisor to the Dean of the McGill University School of Medicine for licensing and commercialization.

He has been honored by Standard and Poor’s as a designated Top 100 “Healthcare Industry Leader”, recognized by Linkedin as a “Top Voice in Venture Capital, Entrepreneurship, and Fundraising”, award winning Google Scholar in Entrepreneurship, a contributing author of healthcare entrepreneurship and venture capital at Fast Company, and has been featured on CNBC and in numerous conferences and publications as one of the leading healthcare investors, strategists, futurists and entrepreneurs in drug discovery/development, biotechnology and AI and digital healthcare.

Over the past 23 years he personally founded 6 startups, lead Endeavor Venture Funds to 140 investments including Moderna and Grail, has served as Senior Strategic Healthcare Advisor for Fortune 500 Companies including McKinsey, Goldman Sachs, Bain Capital, BlackRock, American Express, AIG, Fidelity, Tiger Global, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, and Novartis, and has developed Endeavor into a thriving ecosystem of partnerships with BioPharma, Digital Health, and Big Tech companies, world class CEO entrepreneurs, start-up accelerators, and prominent Ivy League universities, medical centers, and business schools like Harvard, Columbia, MIT, NYU, Oxford, McGill and Johns Hopkins.